Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360387 | 0.85 | GAA (0.57) | GAAMAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL8286971 | 0.83 | GAA (0.56) | GAAMAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL23136224 | 0.81 | GAA (0.60) | GAAMAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL10073072 | 0.80 | KMT2A (0.63) | GAAMAPTKMT2AMEN1MAPK8 | |
| SCHEMBL11812817 | 0.80 | KMT2A (0.63) | GAAMAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL1515916 | 0.79 | GAA (0.53) | GAAMAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL6433174 | 0.79 | HPGD (0.56) | GAAMAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL30623889 | 0.78 | ALDH1A1 (0.66) | GAAMAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL20837329 | 0.78 | ALDH1A1 (0.66) | GAAMAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL5948114 | 0.78 | MAPT (0.66) | GAAMAPTHPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158783-B2 | MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158783-B2 | MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | PNLIP, APOB, MTPN | GAA 398/4885MAPT 2841/4885HPGD 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.